All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IDE196,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Ideaya Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 24, 2020
Details:
The study will evaluate IDE196 and crizotinib combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including metastatic uveal melanoma (MUM), skin melanoma, lung cancer and colorectal cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IDE196,Binimetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Ideaya Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 18, 2020
Details:
IDEAYA and Pfizer will form a Joint Development Committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ASO-Centyrin drug conjugates
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Ionis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 06, 2020
Details:
Ionis has exercised an option to obtain a license to an antisense oligonucleotide (ASO)-Centyrin drug conjugate. Ionis is using Aro’s CENTYRIN technology to enhance activity of ASOs via tissue-specific delivery for efficient inhibition of disease-causing RNAs and proteins.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nirogacestat,PF‐06863135
Therapeutic Area: Oncology Product Name: PF-03084014
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 05, 2020
Details:
Pfizer will sponsor and conduct the Phase 1b/2 study to evaluate the safety, tolerability and preliminary efficacy of the nirogacestat and PF‐06863135 combo, and will assume all costs associated with the study, other than expenses related to the manufacturing of nirogacestat.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZEN-3694,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: ZEN-3694
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2020
Details:
First clinical Study to Combine ZEN-3694 with BMS’s immune checkpoint inhibitors nivolumab and ipilimumab for treatment of ovarian cancer .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $77.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 29, 2020
Details:
Dewpoint Therapeutics works on organelles inside cells called biomolecular condensates, which it believes can be harnessed to treat diseases including cancer and rare genetic disorders. Condensates are membrane-less droplets that help cells perform vital functions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Paxalisib
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Kazia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 22, 2020
Details:
The collaboration aims at investigating the use of Kazia’s new drug, paxalisib (formerly GDC-0084), in primary central nervous system (CNS) lymphoma, a potential new indication for the drug. DFCI will initiate an open-label phase II clinical trial of paxalisib in PCNSL.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Erasmus University Medical Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
Median survival was approximately two-fold higher, that is 200%, in the Ampligen arm as compared to the historical controls.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PBCAR269A,Nirogacestat
Therapeutic Area: Oncology Product Name: PBCAR269A
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: SpringWorks Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 21, 2020
Details:
PBCAR269A, Precision’s allogeneic CAR-T cell therapy candidate targeting B-cell maturation antigen, will be evaluated in combination with nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in patients with relapsed or refractory multiple myeloma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CAR T cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Servier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 17, 2020
Details:
Under the terms of the new development and commercial license agreement between Servier and Precision, companies have added two additional hematological cancer targets beyond CD19 and two solid tumor targets to its CAR T development and commercial license agreement.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
